Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women
brief summary
Study Objectives: Primary: • To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: • To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium
detailed description
This is a randomized, double-blind, placebo-controlled Phase 2A study of vaginal AZU-101 in healthy postmenopausal female participants with moderate to severe vulvovaginal atrophy (VVA) with no contraindications to selective estrogen receptor modulators (SERMs). AZU-101 is a vaginal formulation of lasofoxifene tartrate, a SERM that has high affinity to both estrogen receptor (ER) alpha (ERα) and ER beta (ERβ). This study plans to evaluate 3 doses of AZU-101 (1, 0.5, and 0.1μg) and placebo. Results of the first cohort (1μg AZU-101) will direct additional dosing cohorts (0.5 and 0.1μg AZU-101).
Safety and tolerability will be measured by vital signs, electrocardiogram (ECG) parameters, and the incidence of Treatment-Emergent Adverse Events (TEAEs) and concomitant treatments. The PK profile will be assessed using peak plasma concentration (Cmax), time to peak plasma concentration (tmax), and area-under-the-concentration-time-curve from time zero to infinity (AUC0-∞). Efficacy will be evaluated using vaginal pH, the vaginal Maturation Index (percentage of vaginal parabasal cells and superficial cells), and identification of the most bothersome symptom to the subject (dyspareunia, vaginal dryness, or vaginal irritation/itching).
Number of participants (planned): Up to approximately 90 healthy postmenopausal females, 45 to 60 years of age.
official title
A Double-blind, Randomized, Placebo-controlled Proof oF Concept Clinical Study to Evaluate the Safety, Pharmacokinetics, AND Pharmacodynamics of Vaginal AZU-101 (Lasofoxifene Tartrate) in Postmenopausal Women